Thiazolidinediones News and Research

RSS
Thiazolidinediones are adjunctive therapies for diabetes mellitus (type 2) and related diseases.
Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Studies show AHA's Life's Simple 7 and Diabetes Shared Care Program reduce lifetime risk of heart failure

Studies show AHA's Life's Simple 7 and Diabetes Shared Care Program reduce lifetime risk of heart failure

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

Anti-diabetic medication activates brain sensors, promotes weight gain

Anti-diabetic medication activates brain sensors, promotes weight gain

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

New research suggests potential role for MEK inhibitors in type 2 diabetes

New research suggests potential role for MEK inhibitors in type 2 diabetes

'Achilles heel' in metabolic pathway could stop growth of lung cancer cells

'Achilles heel' in metabolic pathway could stop growth of lung cancer cells

Short-term use of DPP-4 inhibitors does not increase risk for pancreatic cancer

Short-term use of DPP-4 inhibitors does not increase risk for pancreatic cancer

Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Study explores new ways to improve medications to treat type 2 diabetes

Study explores new ways to improve medications to treat type 2 diabetes

Novo Nordisk launches insulin delivery device NovoPen Echo in the U.S.

Novo Nordisk launches insulin delivery device NovoPen Echo in the U.S.

DPP-4 inhibitors may reduce risk of autoimmune diseases

DPP-4 inhibitors may reduce risk of autoimmune diseases

Combinations of sEH inhibition and PPARγ activation have beneficial effects on cardiometabolic syndrome

Combinations of sEH inhibition and PPARγ activation have beneficial effects on cardiometabolic syndrome

Study describes pharmacological action of TZDs directly on pancreas

Study describes pharmacological action of TZDs directly on pancreas

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Common diabetes treatment may cause bladder cancer

Common diabetes treatment may cause bladder cancer

Abscisic acid has anti-inflammatory effects in the lungs and gut

Abscisic acid has anti-inflammatory effects in the lungs and gut

Diabetes drug raises bladder cancer risk

Diabetes drug raises bladder cancer risk

Pioglitazone may raise bladder cancer risk

Pioglitazone may raise bladder cancer risk